Cardiovascular Disease Diagnostics

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

• Study Reliability and Reporting Limitations
• Disclaimers
• Data Interpretation & Reporting Level
• Quantitative Techniques & Analytics
• Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. Industry Overview

• Market Analysis
• Analysis by Product Type
• Cardiology Diagnostic Imaging: Future Outlook
• Heart -Facts and Figures
• Swift Growth in Cardiovascular Disease Devices Market
• Cardiovascular Diseases Damaging Human Health
• Mounting Healthcare Costs- “A Real Concern for Economies”
• Competition in the Cardiac Diagnostics Market
• Market Trends
• Advancement of POC Testing Propels Cardiovascular Diagnostics Market
• Demand on Rise for POC Cardiac Markers
• Minimal Invasive Procedure Hogs the Limelight of Cardiovascular Treatment
• Advancements in Alternate-Site Coagulation Monitoring
• Novel Imaging Techniques Boost In vivo Diagnostic Market
• Strong Demand for Risk Assessment Markers
• New Technologies Bring Diagnostics Closer to Patients
• Trends Cited in the Imaging Technologies Market
• CT Scanners
• MRI
• Move Towards Efficient Patient Data Management

2. CVD - Cause and Risk Factors

• CVD - Global Facts
• Atherosclerosis - Leading Cause for CVD
• Risk Factors
• Irreversible Risk Factors
• Increasing age
• Sex (gender)
• Heredity (including Race)
• Risk Factors that can be controlled
• Tobacco Smoke
• High Blood Cholesterol
• LDL Cholesterol
• HDL Cholesterol
• Triglyceride levels
• Hypercholesterolemia - Conditions Associated with Cholesterol Level
• High Blood Pressure
• BP - Leading Cause of Cardiovascular Disease in Young Adults
• Physical Inactivity
• Obesity and Overweight
• Diabetes Mellitus
• Cardiovascular Disease and Homocysteine Levels
• Measures for Reducing Cardiovascular Diseases

3. Cardiovascular Disease and Conditions

• Angina Pectoris
• Arrhythmias
• Sudden Cardiac Death (SCD)
• Stroke
• Congestive Heart Failure
• Cardiovascular Disease Involving Transplant Patients

4. Diagnostic Tests for Cardiovascular Diseases

• In-Vitro Cardiovascular Diagnostics
• Cholesterol Testing
• Use of Markers
• Creatine Kinase MB
• Troponin T and Troponin I
• C-reactive Protein
• Plasminogen Activator Inhibitor-1
• D-Dimer
• Thrombus Precursor Protein
• Other Cardiac Markers
• Demand Grows for Risk Assessment Markers
• A Step Forward in Cardiovascular Risk Assessment
• In Vivo Diagnostic Tests
• Computer Imaging / Tomography
• Electron Beam Computer Tomography (EBCT)
• Appropriate Conditions for EBCT Diagnosis
• Cardiac Positron Emission Tomography (PET)
• Digital Cardiac Angiography/ Digital Subtraction Angiography
• Magnetic Resonance Imaging (MRI)
• Single Photon Emission Computed Tomography (SPECT)
• Echocardiography
• Different Types of Echo-techniques
• M-mode (Motion mode, One-dimensional)
• Two-Dimensional (Cross-sectional)
• Stress Echocardiogram (Stress Echo)
• Transesophageal Echocardiogram (TEE)
• Risks
• Ultrasound Tests
• Doppler Ultrasound
• Intravascular Ultrasound
• Working
• Comparative Facts Related to Definitive Diagnosis of Cardiovascular Disease
• Nuclear Cardiology Tests
• Applications
• Types of Nuclear Cardiology Tests
• Myocardial Perfusion Imaging
• Applications
• Risks
• Ventricular Function Test
• Types:
• Testing Cardiac Stress
• Cardio Vascular Disease Diagnostics Tests in the Pipeline
• Aderis MRE-0470
• CardioMEMS Novel Technology
• Technology Platform

5. Product Launches and Developments

• Philips Rolls Out 256-slice CT scanner, Brilliance iCT Scanner
• Royal Philips Launches Live 3D Transesophageal Echocardiogram Probe
• GE Healthcare Launches Vivid e Ultrasound Systems
• Cardionetics Launches ECG Monitor for 24-Hour Real-Time Cardiac Diagnosis
• Siemens Launches Imaging Release for the ACUSON Sequoia Platform
• GE Healthcare Launches Version 2.0 of Centricity Cardiology CA1000
• GE Healthcare Introduces New Capabilities to CardioSoft Diagnostic Software
• GE Healthcare’s Lightspeed VCT Offers Imaging at 70% Lower Exposure
• Roche Diagnostics Launches cobas h 232 Portable Cardiac Marker System (Outside US)
• Royal Philips Launches New Imaging Tool for Complex Cardiac Arrhythmias
• Siemens Medical Introduces syngo® US, New Echocardiography Solution.
• Dade Behring Introduces CardioPhase® hsCRP Test for Multiple Testing Platforms.
• Shimadzu Launches Two Models in Angiographic Imaging
• Omron Healthcare Introduces Non Invasive Vascular Profiling System
• Abbott Launches XIENCE V, New Coronary Stent System
• Siemens Medical Introduces Acuson AcuNav 8F, an Advanced Ultrasound Catheter…
• BioMérieux Introduces High Performance VIDAS Troponin I Ultra
• Siemens Launches Acuson X300 Ultrasound Platform
• Siemens Releases Web-Enabled CT
• GE Introduces Latest Electrocardiograph Device, MAC 3500
• GE Emphasizes on the Striking Features of New Vivid 7 Dimension ’06
• GE Launches Latest Innova Digital Flat Panel Biplane Imaging Devices
• Medtronic Introduces Latest Range of Implantable Cardiac Defibrillators
• Philips Introduces Web Based Cardiac Tools
• Siemens Showcases Solutions for Cardiac Problems Through Molecular Imaging
• Siemens Presents Advancements in Echocardiography
• Siemens Debuts syngo BEAT
• Siemens Combines syngo® Dynamics with Soarian® for Cardiovascular EPR
• GE Healthcare Unveils CardIQ Fusion
• GE Introduces VCT
• GE Unveils Dynamic VUE
• GE Launches CardIQ Xpress
• GE Presents the Ventri for Cardiac Imaging
• GE Introduces High Definition Magnetic Resonance System
• Dade Behring Unveils CardioPhase(R) hsCRP Test
• Siemens Launches Encompass III on C512 Ultrasound Platform
• Siemens Launches Four New CT Clinical Engines
• Omron Launches HEM-9000AI Cardiovascular Diagnostic Tool
• Corgenix Introduces Predictive Cardiovascular Diagnostic Kit, AtherOx™
• Philips Introduces HD11 XE Cardiology Ultrasound System
• Siemens Introduces Biplane FD Cardiology System
• Siemens Introduces Syngo Circulation Software for CT Tomography
• Siemens Introduces SOMATOM Definition for Cardiac Imaging
• Dade Behring Unveils Homocysteine Test on BN(TM) Systems
• Roche Unveils Cardiac pro-BNP Test
• Philips Introduces HD11 XE
• Corgenix Unveils AtherOx(TM)
• GE Healthcare Unveils Breakthrough Imaging Technology
• Philips Launches Products to Detect Heart Problems
• Philips Unveils Computed Tomography and EP Planning package
• Philips Widens Magnetic Resonance Kitty
• New Cardiac Monitoring Products from Philips
• Siemens Launches Image-Arena
• Siemens Announces New Procam-Calculator Combined with CT Examination
• Siemens Medical Solutions Launches Axiom Artis dTA
• GE Healthcare Unveils Vivid i
• GE Healthcare Presents Fully Integrated 4D Cardiovascular Ultrasound System
• GE Healthcare Debuts New Imaging System
• New Discovery PET/CT Systems from GE Healthcare
• SonoSite Presents SonoCalc IMT Software
• Dade Behring Introduces High Sensitivity Troponin I Assay
• Biosite Unveils New Diagnostic Test
• MDS Diagnostic Services Unveils New Test to Prevent Heart Disease
• diaDexus Develops PLAC Test
• Siemens Introduces New Nuclear Cardiology Imaging System
• Roche Diagnostics Receives U.S. Clearance and European CE Mark
• Camtronics Unveils Cardiovascular Screening Software
• Mayo Pioneers New Enzyme-Based Cardiovascular Risk Assessment Test

6. Recent Industry Activity

• Siemens Medical acquires Dade Behring
• Inverness Medical Innovations Acquires Cholestech
• Acrongenomics, Pearson and Molecular Enter into Joint Venture
• Cholestech Teams Up with Onsite Health Diagnostics
• Lipomics to Collaborate with Agilent Technologies to Develop Diagnostic Tests.
• Transgenomic and Fiuotecnica Renew Collaboration Agreement
• Alteon and BioRap Technologies Enter into an Agreement
• IM Medical Acquires New Technology for Detecting Cardiovascular Diseases
• Medtronic Establishes New Business Entity
• Siemens Medical Acquires Bayer Healthcare’s Diagnostics Unit
• Spacelabs Acquires Ferraris’ Cardiac Unit
• Global Immune Takes over Primedical International
• Siemens Acquires Diagnostics Products
• Cholestech and Life Line Enter into Collaboration
• LipoScience Signs an Agreement with ARUP
• Philips Acquires Witt Biomedical
• CardioDynamics Enters into an OEM Agreement with Shenzhen Mindray
• Biosense Enters into Strategic Partnership with Siemens Medical Solutions
• Dade Behring Approved the Use of FSAP Antibodies by American Diagnostica
• Abbott Receives Non-exclusive Sublicense for Diagnostic Use of PIGF
• Nanogen Acquires Spectral’s Cardiac Test Division
• Varian Enters into Alliance with LipoScience to Jointly Develop NMR System
• Cardiac Services Professionals Establishes eCardio Diagnostics
• Response Biomedical Wins Nonexclusive License Rights for NT-proBNP and Troponin T
• Biomerieux gains Nonexclusive License for NT-proBNP
• Philips and PMI Ink an Agreement for Outpatient Facility
• LipoScience Enters into an Agreement with LabCorp
• Abbott and Cleveland Clinic to Co-develop Myeloperoxidase Cardiac Test
• Abbott Receives 510(k) Clearance from FDA for Myoglobin Test
• FDA Clears Additional Claim for Biosite’s Triage(R) BNP Test
• Biosite Inks an Agreement with University of Mainz
• Dade Behring Receives FDA Clearance for Advanced D-Dimer Assay
• Nanogen Acquires SYN•X Pharma
• GE Takes Over Amersham Plc
• St. Jude Medical Acquires Irvine Biomedical and Epicor
• SonoSite Snaps Up SonoMetric
• CardioDynamics Purchases Vermed
• Philips and EP MedSystems Announce an Alliance Involving Electrophysiology Solutions
• Toshiba and ViTAL Enters into an Alliance with Johns Hopkins University School of Medicine
• Response Biomedical Collaborates with Shionogi
• Terumo Signs Agreement with Spencer Technologies
• Spectral Diagnostics Announces Agreement with NGC Medical
• Philips Signs Agreement with Fletcher Allen Health Care
• Spectral Diagnostics Enters into an Agreement with Cardinal Health
• Siemens Signs Agreement with MediGuide
• Biosite Enters into Agreement with DMI BioSciences
• Cambridge Heart Enters into Agreement with Del Mar Reynolds
• Cholestech Enters into an Agreement with Itamar Medical
• Siemens Enters into a Contract with HiPGraphics
• Abbott Announces US Clearance for Axis-Shield’s BNP Test for Use on AxSYM
• Cholestech Announces FDA 510(k) Approval for hs-CRP Test
• Dade Behring Bags FDA Clearance NT-proBNP Test
• Dade Behring Receives FDA Clearance for N High Sensitivity CRP Assay
• EP-4 Computerized Cardiac Stimulator Bags FDA Approval
• Biosite Adds two new offices
• Bayer Diagnostics Enhances BNP Assay Offering Globally
• EP MedSystems Garners CE Approval for ALERT Deflectable CS Catheter in Europe
• Cambridge Heart Inc and Quinton Cardiology Systems Renew Pact
• EPIX and Schering AG Extends Collaboration Agreement
• Siemens Ultrasound and TomTec Imaging Systems Announces Agreement
• FIT Biotech Plc Acquires Xenerate Ab to Develop Innovative Cardiovascular Devices
• Beckman Coulter Enters into Agreement with Biosite
• Dade Behring Garners Non-exclusive Rights for a Key Cardiac Marker
• Bracco Diagnostics Inc., Joins Hand with Eastern Isotopes Inc to Develop CardioGen-82®
• New Lab Test from diaDexus Receives FDA Clearance
• Hypertension Diagnostics Receives SDA Approval in China

7. Focus on Select Global Players

• Abbott Diagnostics (USA)
• Biosite Inc. (USA)
• Cambridge Heart, Inc. (USA)
• Cholestech Corp. (USA)
• EP Medsystems (USA)
• GE HealthCare (USA)
• Liposcience, Inc. (USA)
• Philips Medical Systems (USA)
• Roche Diagnostics (Switzerland)
• Siemens Medical Solutions (Germany)

8. Global Market Perspective

• Table 1: World Recent Past, Current & Future Market Analysis for Cardiovascular Disease Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 2: World Long-term Projections for Cardiovascular Disease Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 3: World 10-Year Perspective for Cardiovascular Disease Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)
• Table 4: World Recent Past, Current & Future Market Analysis for Cardiovascular In Vitro Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 5: World Long-term Projections for Cardiovascular In Vitro Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 6: World 10-Year Perspective for Cardiovascular In Vitro Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)
• Table 7: World Recent Past, Current & Future Market Analysis for Cardiovascular In Vivo Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 8: World Long-term Projections for Cardiovascular In Vivo Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 9: World 10-Year Perspective for Cardiovascular In Vivo Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)

III. MARKET

1. The United States

• A. Market Analysis
  • Startling Facts Related to Cardiovascular Diseasein the US
  • Cardio Vascular Disease (CVD) - An Overview
  • Table 10: Prevalence of Cardiovascular Disease in the US in the Recent Past (2004) (includes corresponding Graph/Chart)
  • Table 11: Percentage Breakdown of Deaths from Cardiovascular Diseases in the USin the Recent Past (2004) (includes corresponding Graph/Chart)
  • Table 12: Prevalence of Cardiovascular Diseases among Americans by Age (Age 20 and Older) and Sex in the Recent Past (2004) (includes corresponding Graph/Chart)
  • Table 13: A Factoid of CHD and MI in the US in the Recent Past (2003) (In Million)
  • Startling facts related to Stroke in US
  • Table 14: A Factoid of Stroke in the US in the Recent Past (2003) (In Million)
  • Incidence of Coronary Heart Disease
  • Mortality rate of CHD
  • Table 15: Annual Number of Americans Having Diagnosed Heart Attack by Age and Sex in the Recent Past (2004) (includes corresponding Graph/Chart)
  • Table 16: Prevalence of CHD by Age and Sex in the Recent Past (2004) (In % population) (includes corresponding Graph/Chart)
  • Arrhythmias
  • CAD Diagnostics
  • PVD Diagnostics
  • Medicare Reimbursement Set for CPT Code 83704
  • Competitive Glance
  • Point-of-Care (POC) Diagnostic Market in the US
  • Table 17: Leading Players in the US POC Cardiac Market (2004) - Percentage Breakdown by Value Sales for Biosite, Dade Behring, Spectral Diagnostics, Roche and Others (includes corresponding Graph/Chart)
  • Review of Major Players
  • Abbott Diagnostics
• Biosite Inc
  • Cambridge Heart, Inc
  • Cholestech Corp
  • EP Medsystems
  • Liposcience, Inc.
  • Philips Medical Systems
  • Product Launches/Developments
  • Strategic Developments
• B. Market Analytics
  • Table 18: US Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 19: US Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 20: US 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2000, 2007 & 2010

2. Canada

• A. Market Analysis
  • Product Launch
  • Strategic Developments
• B. Market Analytics
  • Table 21: Canadian Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 22: Canadian Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 23: Canadian 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2000, 2007 & 2010

3. Japan

• A. Market Analysis
  • Strategic Developments
• B. Market Analytics
  • Table 24: Japanese Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 25: Japanese Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 26: Japanese 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2000, 2007 & 2010

4. Europe

• A. Market Analysis
  • European Union Cardiovascular DiseasesFact Sheet
  • In Vivo Diagnostics - Leading Segment
  • Germany - The Largest European Market
  • Product Launches
• B. Market Analytics
  • Table 27: European Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 28: European Long-term Projections for Cardiovascular Disease Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 29: European Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 30: European Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 31: European 10-Year Perspective for Cardiovascular Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia & Rest of Europe Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)
  • Table 32: European 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2000, 2007 & 2010

4a. France

• A. Market Analysis
  • Strategic Development
• B. Market Analytics
  • Table 33: French Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 34: French Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 35: French 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2000, 2007 & 2010

4b. Germany

• A. Market Analysis
  • Siemens Medical Solutions - A Major Player
  • Product Launches
  • Strategic Developments
• B. Market Analytics
  • Table 36: German Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 37: German Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 38: German 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2000, 2007 & 2010

4c. Italy

• A. Market Analysis
  • Strategic Developments.
• B. Market Analytics
  • Table 39: Italian Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 40: Italian Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 41: Italian 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2000, 2007 & 2010

4d. The United Kingdom

• A. Market Analysis
  • UK Cardiovascular Diseases Fact Sheet
  • Key Player Review
  • GE HealthCare
• B. Market Analytics
  • Table 42: UK Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 43: UK Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 44: UK 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2000, 2007 & 2010

4e. Spain

• Market Analysis
• Table 45: Spanish Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 46: Spanish Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 47: Spanish 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2000, 2007 & 2010

4f. Russia

• Market Analysis
• Table 48: Russian Recent Past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 49: Russian Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 50: Russian 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2000, 2007 & 2010

4g. Rest of Europe

• A. Market Analysis
  • Roche Diagnostics - A Key Swiss Player
• B. Market Analytics
  • Table 51: Rest of Europe Market for Cardiovascular Disease Diagnostics - Recent Past, Current & Future Market Analysis by Product Segment for In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 52: Rest of Europe Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 53: Rest of Europe 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2000, 2007 & 2010

5. Asia Pacific

• A. Market Analysis
  • Cardiovascular Market in Asia-Pacific
  • China
  • Cardiovascular Disease Patients Overview
  • Treatment Providers and Hospitals Overview
  • Hospitals
  • Table 54: Cardiovascular Special Treatment Hospitals in China: 1991-2011(In numbers) (includes corresponding Graph/Chart)
  • Chinese Cardiovascular Disease Treatment as aPart of Overall Health Care Industry
  • Table 55: Cardiovascular Diseases Treatment inChina: 1991-2011(In US$ million) (includes corresponding Graph/Chart)
  • Strategic Developments
• B. Market Analytics
  • Table 56: Asia-Pacific Market for Cardiovascular Disease Diagnostics - Recent Past, Current & Future Market Analysis by Product Segment for In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 57: Asia-Pacific Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 58: Asia-Pacific 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2000, 2007 & 2010

6. The Middle East

• Market Analysis
• Table 59: Middle East Market for Cardiovascular Disease Diagnostics - Recent Past, Current & Future Market Analysis by Product Segment for In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 60: Middle East Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 61: Middle East 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2000, 2007 & 2010

7. Latin America

• A. Market Analysis
  • Strategic Development
• B. Market Analytics
  • Table 62: Latin American Market for Cardiovascular Disease Diagnostics - Recent Past, Current & Future Market Analysis by Product Segment for In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 63: Middle East Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - In Vitro Diagnostics and In Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 64: Latin American 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for In Vitro Diagnostics and In Vivo Diagnostics Markets for 2000, 2007 & 2010